SAINT-BRUNO-DE-MONTARVILLE, Quebec, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”), today provides an update regarding its previously announced strategic alternatives review. On October 16, 2025, the Company had announced an extension of its forbearance agreement with its main senior lenders and Investissement Québec to January 30, 2026 (the “Forbearance Agreements”). The amended terms required maintaining $1 million in liquidity and meeting a minimum trailing t ...

Core Viewpoint - Aterian, Inc. has initiated a formal process to evaluate strategic alternatives aimed at maximizing shareholder value, which may include asset sales, company sales, mergers, or other strategic actions [1][3]. Company Overview - Aterian, Inc. is a consumer products company that builds and acquires leading e-commerce brands across various categories, including home and kitchen appliances, health and wellness, and air quality devices [5]. - The company operates on major online marketplaces such as Amazon, Walmart, and Target, as well as its own direct-to-consumer websites [5]. - Aterian's brand portfolio includes well-known names like Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct [5]. Strategic Review Process - The Board of Directors has authorized the exploration of strategic alternatives to enhance shareholder value, reflecting concerns that the current market valuation does not represent the true value of the brand portfolio [1][3]. - Aterian has engaged A.G.P / Alliance Global Partners to assist in this strategic review, with legal counsel provided by Paul Hastings LLP [4]. Market Position and Challenges - Despite having a strong portfolio and a global omni-channel sales presence, Aterian acknowledges ongoing business and category challenges that necessitate the exploration of strategic options [3]. - The CEO emphasized the importance of approaching the review thoughtfully while maintaining high levels of customer and partner service [3].

Core Points - Atkore Inc. has announced the sale of its Tectron mechanical tube product line and manufacturing facility to Lock Joint Tube, aiming to enhance focus on its electrical infrastructure portfolio and deliver greater shareholder value [1][2][3] Company Overview - Atkore Inc. is a leading manufacturer of electrical products for various applications, including commercial, industrial, data center, telecommunications, and solar, with 5,400 employees and $2.9 billion in sales for fiscal year 2025 [4]

Core Viewpoint - Neuphoria Therapeutics Inc. is urging stockholders to vote for its two nominees for the Board of Directors, emphasizing their qualifications and the importance of stability during the ongoing strategic review process [1][2][4]. Group 1: Board Nominees and Voting - Neuphoria is advocating for stockholders to vote "FOR" its nominees, Peter Miles Davies and David Wilson, who possess significant expertise in investment and capital allocation relevant to the company's strategic review [2][8]. - A dissident stockholder, Lynx1 Master Fund LP, has nominated its own candidates, and Neuphoria is urging stockholders to vote "WITHHOLD" on these nominees [3][12]. - The company emphasizes that introducing inexperienced directors could disrupt the strategic review process and negatively impact value creation [11][13]. Group 2: Strategic Review Process - Neuphoria's Board is committed to maximizing value for all stockholders and is conducting a comprehensive review of strategic alternatives with the help of independent financial and legal advisors [4][6]. - The strategic review process is ongoing, with H.C. Wainwright & Co. serving as the financial advisor, and the Board is evaluating various proposals from interested parties [6][7]. - The company believes that maintaining continuity on the Board is critical to successfully completing the strategic review and maximizing value [8][21]. Group 3: Financial Position and Pipeline - Neuphoria has raised capital through its at-the-market program to ensure a strong financial position ahead of anticipated clinical data readouts, which is crucial for negotiating favorable terms with investors [15][16]. - Following a negative data readout from the AFFIRM-1 Phase 3 trial, the company is focused on exploring strategic alternatives and pursuing other pipeline programs [16][24]. - The company’s financial preparedness enhances its credibility and ability to attract high-quality strategic opportunities, thereby maximizing long-term stockholder value [18][20].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - Atkore Inc. reported a net sales of $2.9 billion for fiscal 2025, marking a decrease of 11.0% compared to the previous year, primarily due to lower average selling prices and divestitures [4][16][18] - The company experienced a net loss of $15.2 million for fiscal 2025, a significant decline from a net income of $472.9 million in fiscal 2024, driven by lower operating income [18][19] - Adjusted EBITDA for fiscal 2025 decreased by 49.9% to $386.4 million, reflecting the impact of reduced sales and increased costs [19] Fourth Quarter Highlights - In Q4 2025, net sales were $752.0 million, down 4.6% from $788.3 million in Q4 2024, primarily due to lower average selling prices [6][7] - The company reported a net loss of $54.4 million in Q4 2025, compared to a net income of $73.1 million in the same quarter of the previous year [9][11] - Adjusted EBITDA for Q4 2025 was $70.9 million, a decrease of 49.4% from $140.1 million in Q4 2024 [10][13] Segment Performance - Electrical segment net sales decreased by 8.1% to $518.9 million in Q4 2025, attributed to lower average selling prices and divestitures [12] - Safety & Infrastructure segment net sales increased by 4.0% to $233.4 million in Q4 2025, driven by higher volumes [14][15] Financial Metrics - Gross profit for Q4 2025 was $147.8 million, down from $216.1 million in Q4 2024, with gross margins decreasing from 27.4% to 19.7% [8][36] - The company repurchased $100.0 million in outstanding shares and paid dividends totaling $44.2 million during fiscal 2025 [21][20] - Cash provided by operating activities was $402.8 million, while free cash flow decreased to $295.7 million for fiscal 2025 [20] Outlook - For fiscal 2026, Atkore expects net sales to be in the range of $3.0 billion to $3.1 billion, with an adjusted EBITDA outlook of $340 million to $360 million [6][23]

Core Viewpoint - Astrotech Corporation has initiated a review of strategic alternatives to maximize shareholder value, which may include raising equity capital, reverse mergers, combination transactions, and potential sales of parts of the business [1][3]. Group 1: Strategic Review - The Board of Directors is exploring various strategic options to enhance shareholder value without a set deadline for completion [3]. - Potential actions under consideration include raising equity capital, reverse mergers, and the sale of all or part of the Company's business [1]. Group 2: Business Confidence - The Company expresses confidence in its mass spectrometry and gas chromatography technologies, targeting large end markets such as explosives trace detection and environmental testing [2]. - Astrotech is advancing its strategic sales plans and customer relationships globally while considering options to scale the business effectively [2]. Group 3: Subsidiaries Overview - Astrotech operates through subsidiaries that focus on specialized markets: - 1st Detect develops trace detection systems for security and narcotics screening [5]. - AgLAB designs process analyzers for the agriculture industry [5]. - Pro-Control provides solutions for chemical process control in industrial manufacturing [5]. - EN-SCAN, Inc. offers portable environmental testing solutions integrating gas chromatography and mass spectrometry [5].

Core Insights - Sensei Biotherapeutics, Inc. has reported its financial results for Q3 2025, highlighting a significant strategic shift in its operations [1][4][5] - The company has decided to discontinue the development of its lead product candidate, solnerstotug, and is exploring various strategic alternatives to maximize shareholder value [2][3] Financial Performance - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $25.0 million, down from $41.3 million at the end of 2024 [4] - Research and Development (R&D) expenses for Q3 2025 were $2.5 million, a decrease from $4.6 million in Q3 2024, primarily due to lower personnel and facility costs [4] - General and Administrative (G&A) expenses also decreased to $2.3 million in Q3 2025 from $3.2 million in Q3 2024, attributed to reduced personnel costs [5] - The net loss for Q3 2025 was $4.6 million, compared to a net loss of $7.3 million in the same quarter of the previous year [5][8] Strategic Review and Workforce Reduction - The company has implemented a workforce reduction of approximately 65% to conserve cash while it reviews strategic alternatives [2][3] - A small team will remain to assist in exploring these alternatives and managing the cessation of development activities [3] Balance Sheet Highlights - As of September 30, 2025, total assets were reported at $27.6 million, down from $45.4 million at the end of 2024 [10] - Total liabilities decreased to $4.6 million from $7.0 million, while total stockholders' equity fell to $23.0 million from $38.4 million [10]

Core Viewpoint - Centerspace's Board of Trustees has initiated a review of the company's strategic alternatives, considering options such as a sale, merger, or continuing its independent business strategy [1][2]. Group 1: Strategic Review - The review process does not have a set timetable, and no decisions regarding potential strategic alternatives have been made at this time [2]. - Centerspace has engaged BMO Capital Markets Corp. as its financial advisor and Wachtell, Lipton, Rosen & Katz as legal counsel to assist in the review [3]. Group 2: Company Overview - Centerspace is an owner and operator of apartment communities, with a portfolio of 68 apartment communities comprising 12,941 homes across several states including Colorado, Minnesota, and Utah [4]. - The company has been recognized as a top workplace for the sixth consecutive year in 2025 by the Minneapolis Star Tribune [4].

Core Viewpoint - Neuphoria Therapeutics Inc. is exploring strategic alternatives to enhance its pipeline and maximize stockholder value, including potential mergers, acquisitions, and partnerships [2][3][5]. Strategic Alternatives - The company has engaged H.C. Wainwright & Co. as its exclusive financial advisor to assist in evaluating strategic options [3]. - There is no defined timeline for this exploration, and the company does not guarantee that any strategic alternatives will be finalized [3]. Unsolicited Offer - On November 10, 2025, Neuphoria received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP to acquire all outstanding shares for $5.20 per share in cash [4]. - Lynx1 Master Fund LP also intends to nominate individuals for election to Neuphoria's Board of Directors at the upcoming Annual Meeting [4]. Board of Directors' Response - Neuphoria's Board is committed to acting in the best interests of all stockholders and will evaluate the unsolicited offer in conjunction with its strategic alternatives review [5]. - The Board will present its recommendations regarding director nominees in the proxy statement for the 2025 Annual Meeting [6]. Annual Meeting Details - The 2025 Annual Meeting is scheduled for December 12, 2025, with a record date of October 15, 2025 [6]. - Stockholders are not required to take any action at this time [7]. Company Overview - Neuphoria is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders [9]. - The company previously advanced its lead drug candidate, BNC210, for social anxiety disorder and PTSD but halted its development following unsuccessful clinical trial results [9]. - Neuphoria has a partnership with Merck & Co. for two drugs in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease [9].